Prevalence of hypovitaminosis D and its relation to cardiovascular risk among elderly diabetic female patients

Walaa W. Aly¹, Hend M. Taha¹, Khalid E. Elsorady¹, Wessam E. Saad², Ahmed K. Mortagy¹
¹Geriatric and Gerontology Department, Faculty of Medicine, Ain Shams University.
²Clinical Pathology Department, Ain Shams University Hospitals.

ABSTRACT

Vitamin D deficiency is highly prevalent worldwide and certain groups as elderly persons women and institutionalized persons are particularly prone to severe deficiency. Objective: To identify the prevalence of hypovitaminosis D and its relation to cardiovascular risk among elderly diabetic female patients. Method: A cross sectional study conducted from the first of October 2014 to the end of March, 2016, where 163 elderly diabetic females who attended Ain shams university hospital at that time were included. They underwent careful history taking, body mass index calculation, blood pressure measurement and Serum 25(OH) D measurement, assessment of insulin secretion including fasting serum C-peptide and CPI measurement in addition to assessment of glycemic control by fasting blood sugar estimation. The level of 25 hydroxy vitamin D (25OHD) was measured. Results: The prevalence of vitamin D deficiency (25OHD level <20 ng/mL) and insufficiency (25OHD concentration of 20–29 ng/mL) among elderly Egyptian diabetic female patients are 71.2% and 28.2% resp. There is statistically significant association between vitamin D deficiency and low fasting C peptide level and c peptide index. The 3 independent predictor of the presence of vitamin D deficiency were types of diabetic medications, low C-peptide and CPI values and upon logistic regression analysis for these 3 variables, lower CP level was an independent predictor of the presence of vitamin D deficiency. Results showed a weak negative correlation between serum 25(OH)D, systolic BP, BMI and HOMA IR in studied subjects. Conclusion: Prevalence of vitamin D deficiency among elderly Egyptian diabetic female patients is 71.2%. There is statistically significant association between vitamin D deficiency and low fasting C peptide level and c peptide index.

Keywords: Hypovitaminosis D, cardiovascular risk, diabetic females.

How to cite this article:
Walaa W. Aly, Hend M. Taha, Khalid E. Elsorady, Wessam E. Saad, Ahmed K. Mortagy. Prevalence of hypovitaminosis D and its relation to cardiovascular risk among elderly diabetic female patients. International Journal of Aging Research, 2018, 1:15
INTRODUCTION

Hypovitaminosis D has become pandemic and is now seen in every country in the world. It has been estimated that more than one billion people worldwide are either vitamin D deficient or insufficient [1]. Older people are more likely to have lower serum 25(OH)D concentrations [2], partly due to reduced ability to synthesize vitamins with increasing age [3].

Alarming levels of vitamin D deficiency among Egyptian females across all age groups have been demonstrated, prevalence of hypovitaminosis D is approximately 77.2% among healthy geriatric population [1]. There is evident relationship between vitamin D adequacy and various human disease including skeletal and extra skeletal manifestations. As it has a role in many metabolic processes such as glucose metabolism [4]. Prevalence of hypovitaminosis D among diabetic patients exceeds 80 % in various population, also vitamin D status is inversely related to glycemic control. Thus, a poor glycemic control is associated with low vitamin D levels [5], as 25(OH)D plays an important role in glucose homeostasis via different mechanisms. It improves insulin sensitivity of the target cells (liver, skeletal muscle, and adipose tissue [6, 7]. In addition, recent research suggests that low 25(OH)D concentrations may be related to insulin resistance [9].

In addition to vitamin D role in the pathogenesis of DM, there is a growing body of evidence suggests that low levels of vitamin D may adversely affect the cardiovascular system through several mechanisms [10]. Analyzing data from the Third National Health and Nutrition Examination Survey (NHANES III) showed a strong association between hypovitaminosis D and cardiovascular risk factors including diabetes, high blood pressure and increased body mass index [11].

Hypovitaminosis D is associated with higher risk of metabolic syndrome, a cluster of abdominal obesity, hypertension, hyperglycemia and dyslipidemia which are a major risk factor for cardiovascular disease and mortality [12], as it has an anti-inflammatory effect and negative regulator of the renin-angiotensin system that decreases blood pressure [13].

Insulin resistance is a hallmark of diabetes, obesity, cardiovascular diseases and metabolic syndrome [14]. A number of indices have been used to simplify and improve the determination of insulin resistance [14]. Fasting C-peptide could be used for determination of Insulin resistance, using HOMA modeling [15], as C-peptide concentrations in the peripheral blood are widely accepted as the most appropriate measure of insulin secretion because it is secreted in equimolar amounts with insulin [16, 17]. C peptide index (CPI) could be used as an index of endogenous insulin secretion and insulin resistance, it is not affected by exogenous insulin therapy, hence its value in patients with insulin therapy [18].

The aim of this study was to identify the prevalence of hypovitaminosis D and to detect its relation to cardiovascular risk among Egyptian elderly diabetic female patients.

SUBJECTS AND METHODS

Study design: A cross sectional study.

Setting: Inpatient wards, Ain Shams University Hospital.

Study participants: One hundred and sixty-three elderly diabetic females recruited from the first of October 2014 to the end of March 2016.

After obtaining an informed consent, all participants underwent careful history taking including history of DM and hypertension. All included patients were diabetics on antidiabetic treatment and the associated hypertension was evaluated based on history of hypertension and on blood pressure measurement with a calibrated sphygmanometer at resting state, hypertension was defined as a systolic pressure above or equal 140 mmHg and/or a diastolic pressure above or equal 90 mmHg [19]. Blood Samples were withdrawn during
fasting state after about 8 hours fasting, then collected into plain tubes and centrifuged to separate serum that is stored at -70°C until analysis then referred to Ain shams university hospital blood lab for determination of serum 25(OH)D and fasting serum C-peptide.

Serum 25(OH)D measurement was done using 25(OH)D kits manufactured by DRG instruments GmbH, Marburg, Germany and were analyzed by ELISA methods. Level of 25(OH)D equal or more than 30ng/ml is considered to be sufficient, 10 to less than 30ng/ml is considered to be insufficient, and level less than 10ng/ml is considered as vitamin D deficiency [20].

Fasting serum C-peptide level was done using C-peptide kits manufactured by DRG instruments GmbH, Marburg, Germany and were analyzed by ELISA methods and according to the used C peptide kit, reference range was (0.5-3.2ng/ml), patients were divided into 3 categories:

High CP level: Serum C-peptide level > 3.2 indicating hyperinsulinemic state and insulin resistance,
Normal CP level: Serum C-peptide level 0.5–3.2
Low CP level: Serum C-peptide level <0.5 indicating insulin deficiency state.

All patients underwent assessment of glycemic control by fasting blood sugar estimation utilizing enzyme technique with glucosoxidation. Glycemic control was categorized based on FBS value, normal values were taken as less than 100 mg/dl (normal FBS category) and high in cases with value over or equal to 100 mg/dl (high FBS category).

Assessment of insulin resistance done by HOMA2-IR index which was obtained by the program HOMA Calculator v2.2.2 (The Oxford Centre for Diabetes. Endocrinology & Metabolism. Diabetes Trial Unit. HOMA Calculator. Available from: http://www.dtu.ox.ac.uk/ Accessed March 2009). At the current study, HOMA 2 calculation couldn’t be done for 60 patients whose serum C-peptide level less than 0.6 ng/ml as this value is not accessible at the program so estimation of insulin resistance done for 103 patients only. HOMA-IR makes it possible to define persons with insulin resistance with a single glucose and C-peptide measurement in the fasting state, we used 2.0 as HOMA 2-IR cut-off point to diagnose insulin resistance. Patients with HOMA2-IR ≥ 2.0 were considered insulin resistant and patients with HOMA2-IR index < 2 were not considered insulin resistant [21, 22]. Estimation of B cell function, in addition to fasting serum C-peptide, CPI was used as an indicator for insulin secretion. CPI measurement was done for each participant. The C-peptide index (CPI) was calculated for all participants with the following formula: fasting C-peptide (ng/ml)/fasting glycemia (mg/dl) × 100 [23, 24]. We used CPI value cut off point at 1.1ng/mg. Accordingly, patients were divided into 2 categories:

High CPI: C-peptide index (CPI) value ≥ 1.1 indicating hyperinsulinemic state and insulin resistance
Low CPI: C-peptide index (CPI) value < 1.1 indicating insulin deficiency state [25].

Ethical statement
There is no conflict of interest of any kind, all authors have no financial or any other kind of personal conflicts.

All authors meet the criteria for authorship and are in agreement with the content of the manuscript and have contributed significantly to this work.

STATISTICAL METHODS:
Values were presented as means ± SD or as numbers and proportions, as appropriate. The relations between qualitative variables were evaluated by Chi-square test or Fisher’s exact test, as indicated. Means were compared with Student’s test or analysis of variance.
Quantitative variables were correlated with the use of coefficient of correlation “r”. Variables that were statistically significant in univariate analysis were introduced in a logistic regression model to detect independent predictors of outcome. All tests were bilateral and a P value of 5% was the limit of statistical significance. Analysis was performed by statistical package software IBM-SPSS for MAC, version 24.

RESULTS:

This study was conducted at Ain Shams university hospitals during the time period of about 2 years, 163 elderly diabetic females were enrolled in the study, 71.8% (117) were on insulin therapy and 28.2% (46) were on oral hypoglycemic medication.

Estimation of B cell function and insulin resistance were done for 102 patients only as HOMA 2 calculation couldn’t be done for 60 patients whose serum C-peptide levels were less than 0.6 ng / ml as this value is not accessible at the program. The study was conducted on 163 elderly diabetic females with a mean age of 66.19 ±5.72 years. Serum 25(OH)D was 9.01(±6.04), height was 153.68 cm (±7.22), weight was 79.69 kg (±21.56), and BMI was 33.65 (±8.36). Systolic BP was 128.56 (±19.35), diastolic BP was 79.39 (±11.08), fasting blood sugar was 174.20 (±84.58), serum C peptide (ng/mL) was 2.77 (±3.62), CPI was 1.84 (±2.64) and HOMA IR was 4.13 (±4.09) (Table 1). Prevalence of vitamin D deficiency was 71.2%, vitamin D insufficiency was 28.2% and vitamin D sufficiency was 0.6% (the case with sufficient vitamin D was not enrolled in subsequent comparisons) (Table 2).

There was statistically significant higher prevalence of vitamin D deficiency among diabetics on insulin therapy in comparison to those on oral hypoglycemic drugs. There was statistically significant difference between means of 25(OH)D as regards CP level and CPI. Low fasting serum C peptide level and CPI were found to be significantly related to lower vitamin D level. Vitamin D deficiency was more common among obese patients 79 person out of 110 (68.1%). In comparison to vitamin D insufficiency, vitamin D deficiency was significantly associated with the presence of lower CP level and CPI values. But there was no statistically significant difference between the 2 groups of vitamin D as regards presence of insulin resistance (Table 3). Upon logistic regression analysis done for the 3 variables associated with vitamin D deficiency, lower CP level was an independent predictor of the presence of vitamin D deficiency (Table 4). There was statistically significant association between low C peptide level and presence of vitamin D deficiency (P value 0.000) (Figure 1). There was a positive correlation between serum 25(OH)D and C peptide (ng/mL) and CPI and negative correlation between serum 25(OH)D and Systolic BP, BMI, and, HOMA IR, although not statistically significant. There was statistically significant difference between CP level categories as regards HOMA %B and HOMA IR. High CP level categories significantly associated with higher HOMA %B and HOMA IR. There was statistically significant association between high C peptide level and presence of insulin resistance (P value 0.000), as all patients (52) with high C peptide level are insulin resistant (Figure 2). Similarly, there was statistically significant difference between the 2 categories of CPI as regards fasting blood sugar, 25(OH)D (ng/mL), HOMA %B and HOMA IR. The lower CPI was significantly associated with lower 25(OH)D, C peptide, HOMA %B and HOMA IR (Table 5). There was significant association between high CPI and presence of Insulin resistance (P value 0.000) (figure 3).

There was no statistically significant difference between means of BMI as regards serum 25(OH)D, but the majority of obese patients are vitamin D deficient (P value 0.34).

Upon comparison between means of serum 25(OH)D (ng/mL) in uncontrolled and controlled Systolic blood pressure were 7.77± 4.41 vs.
9.29 ± 5.77 and means of serum 25 (OH) D respectively without statistically significant difference.

Table 1: The clinical characteristics of the study subjects

| Variables               | Range   | Mean ± SD   |
|-------------------------|---------|-------------|
| Age                     | 60.00 - 85.00 | 66.19 ± 5.72 |
| Weight (kg)             | 33.00 - 225.00 | 79.69 ± 21.56 |
| Height (cm)             | 130.00 - 170.00 | 153.68 ± 7.22 |
| BMI                     | 14.28 - 85.73  | 33.65 ± 8.36  |
| Systolic BP             | 80.00 - 210.00 | 128.56 ± 19.35 |
| Diastolic BP            | 50.00 - 100.00 | 79.39 ± 11.08 |
| Fasting blood sugar     | 43.00 - 460.00 | 174.20 ± 84.58 |
| C peptide (ng/mL)       | 0.001 - 19.55  | 2.77 ± 3.62   |
| C Peptide Index (CPI)   | 0.0005 - 19.78 | 1.84 ± 2.64   |
| Serum 25 OH Vit D (ng/mL)| 0.01 - 44.00  | 9.01 ± 6.04   |
| HOMA %B                 | 6.40 - 405.90 | 95.02 ± 81.29 |
| HOMA IR                 | 0.48 - 31.25  | 4.13 ± 4.09   |

Table 2: Serum 25(OH)vitamin D levels among participants

| 25(OH)vitamin D level |
|-----------------------|
| Deficiency No. (%)    | Insufficiency No. (%) | Sufficiency No. (%) | Total No. (%) |
| 116 (71.20)           | 46 (28.20)            | 1 (0.60)            | 163 (100.00) |

Vitamin D deficiency (25OHD level <20 ng/mL) and insufficiency (25OHD concentration of 20–29 ng/mL)

Figure 1: Comparison between 25(OH)D deficiency-insufficiency as regards C peptide level.
Table 3: Comparison between participants with sufficient and insufficient levels of 25(OH) vitamin D, stratified by CP level, CPI value and IR.

| Quantitative Variables | Vitamin D status | Chi-Square |  |
|------------------------|-----------------|------------|----------|
|                        | Deficiency       | Insufficiency | Total    |  |  |
|                        | N (116) | % | N (46) | % | N (162) | % | X² | P-value |
| C Peptide level        | High          | 32.00 | 27.60 | 20.00 | 43.50 | 52.00 | 32.10 | 33.948a | 0.000 |
|                        | Normal        | 26.00 | 22.40 | 25.00 | 54.30 | 51.00 | 31.50 |
|                        | Low           | 58.00 | 50.00 | 1.00  | 2.20  | 59.00 | 36.40 |
| C Peptide Index (CPI) value | High | 45.00 | 38.80 | 32.00 | 69.60 | 77.00 | 47.50 | 12.507a | 0.000 |
|                        | Low           | 71.00 | 61.20 | 14.00 | 30.40 | 85.00 | 52.50 |
| Insulin resistance*    | Yes           | 39.00 | 56.50 | 30.00 | 43.50 | 69.00 | 67.60 | 0.010a | 1.000 |
|                        | No            | 19.00 | 57.60 | 14.00 | 43.10 | 33.00 | 32.40 |
| Type of diabetic medication | Insulin | 90.00 | 77.60 | 27.00 | 58.70 | 117.00 | 72.20 | 5.859a | 0.015 |
|                        | oral hypoglycemic | 26.00 | 22.40 | 19.00 | 41.30 | 45.00 | 27.80 |
| BMI Category           | Obese         | 79.00 | 68.10 | 31.00 | 67.40 | 110.00 | 67.90 | 3.318a | 0.345 |
|                        | Overweight    | 26.00 | 22.40 | 8.00  | 17.40 | 34.00 | 21.00 |
|                        | Normal weight | 11.00 | 9.50  | 6.00  | 13.00 | 17.00 | 10.50 |
|                        | Underweight   | 0.00  | 0.00  | 1.00  | 2.20  | 1.00  | 0.60  |

* Insulin resistance were done for 102 patients.

Table 4: Independent predictors of the presence of vitamin D deficiency.

| The 3 variables associated with vitamin D deficiency | B coefficient values | P value |
|-----------------------------------------------------|----------------------|---------|
| DM on insulin therapy                               | -0.760               | 0.088   |
| Lower C Peptide level                               | 4.022                | 0.000   |
| Lower C Peptide Index (CPI) value                   | -0.021               | 0.971   |

Figure 2: Association between C peptide level and presence of insulin resistance.
Table 5: Comparison between means of high and low CPI categories as regards other quantitative variables.

| Other variables           | CPI value |      |       |       |       |       |      |       |       |       |       |       |       |
|---------------------------|-----------|------|-------|-------|-------|-------|------|-------|-------|-------|-------|-------|-------|
|                           | High (n=77)| low (n=85) |       |       |       |       |       |      |       |       |       |       |       |       |
|                           | Mean ± SD  | Mean ± SD  |       |       |       |       |       |      |       |       |       |       |       |       |
| BMI                       | 34.11 ± 7.34 | 32.95 ± 7.31 | 0.316 |       |       |       |       |       |       |       |       |       |       |
| Systolic BP               | 127.47 ± 16.19 | 129.76 ± 21.87 | 0.446 |       |       |       |       |       |       |       |       |       |       |
| Diastolic BP              | 78.96 ± 10.04 | 80.00 ± 11.85 | 0.547 |       |       |       |       |       |       |       |       |       |       |
| Fasting blood sugar       | 159.16 ± 74.72 | 188.62 ± 90.95 | 0.025 |       |       |       |       |       |       |       |       |       |       |
| C peptide (ng/mL)         | 5.26 ± 3.91  | 0.54 ± 0.78  | 0.000 |       |       |       |       |       |       |       |       |       |       |
| 25 (OH) D (ng/mL)         | 10.25 ± 6.05  | 7.47 ± 4.36  | 0.001 |       |       |       |       |       |       |       |       |       |       |
| HOMA %B                   | 117.12 ± 81.88 | 26.95 ± 13.65 | 0.000 |       |       |       |       |       |       |       |       |       |       |
| HOMA IR                   | 4.83 ± 4.42  | 1.96 ± 1.40  | 0.000 |       |       |       |       |       |       |       |       |       |       |

Figure 3: Association between C Peptide Index (CPI) and presence of Insulin resistance.

DISCUSSION:
The prevalence of hypovitaminosis D is common among postmenopausal women particularly those with diabetes [26]. The results of our study showed that the majority of diabetic elderly female non-supplemented patients have suboptimal vitamin D level. In our study, vitamin D insufficiency was defined as a 25(OH)D level < 30ng/ml, which is in accordance with the recommendation of International Osteoporosis Foundation (IOF). The study showed that the prevalence of vitamin D deficiency is 71.2%, vitamin D insufficiency is 28.2% and vitamin D sufficiency is 0.6%, these results support other previous studies in this field at various countries, including sunny regions of the world and neighboring countries [26, 27]. In a recent study, the prevalence of hypovitaminosis D was higher in diabetic patients than in control
subjects (90% vs. 83%; p<0.01) [28]. It affects 89% of non-supplemented postmenopausal women with T2DM [37]. Deepika et al. [29] showed that patients with T2DM have a very low serum 25(OH)D level and almost all of the patients had vitamin D insufficiency or deficiency.

Vitamin D deficiency is thought to influence DM pathogenesis by affecting either β-cell function, insulin sensitivity, or both [30].

**Role of vitamin D in insulin secretion**

Vitamin D deficiency is associated with impaired insulin secretion, which is a high-risk factor for diabetes [31]. The level of Vitamin D is reported to be lower in diabetic patients than in non-diabetics [9] as vitamin D plays an important role in beta cell functions [32]. Endogenous insulin secretion can be measured by several indices (indices of insulin secretion) including fasting serum C peptide level, HOMA %B and CPI [24, 33-34]. We found statistically significant higher prevalence of vitamin D deficiency among diabetics on insulin therapy in comparison to those on oral hypoglycemic drugs. There was statistically significant difference between means of 25(OH)D as regards CP level and CPI. Mean serum 25(OH)D (ng/mL) is higher among the high C peptide category than low C peptide one being 10.19 vs. 6.07 among the 2 categories, respectively (P value 0.00). Subsequently, there was significant difference as regards vitamin D status and fasting serum C peptide level categories as majority of patients with low C peptide level (98.3%) had vitamin D deficiency (P value 0.00), also mean HOMA %B was higher among the high C peptide category than the normal C peptide one, 126.06 vs. 62.74 resp with statistically significant difference (P value 0.00). Current study found a statistically significant association between low C peptide level and presence of vitamin D deficiency (P value 0.000), that is consistent with a large prospective, randomized, double-blind, placebo-controlled clinical trials [35 - 36]. The current study showed that in comparison to patients on oral hypoglycemic therapy, patients on insulin therapy had significantly lower serum 25(OH) vitamin D levels. There was statistically significant association between insulin therapy and vitamin D deficiency (P value 0.01) as the majority of patients on insulin therapy had vitamin D deficiency 90 patient out of 116 with odds ratio 2.4.

Similarly, considering CPI as an index of endogenous insulin secretion [18], we found a positive correlation between serum 25 (OH) D and CPI value and a significant association between low serum 25(OH)D levels and low CPI, mean serum 25(OH)D was 10.25 ± 6.05 vs. 7.47 ± 4.36 (P value 0.00) among high and low CPI categories, respectively.

**Role of vitamin D in insulin sensitivity**

To determine presence of insulin resistance, HOMA2 calculation was done for 102 patients, who had serum C peptide above 0.6ng/ml and showed that 69 patients (67.6%) had insulin resistance and 33 patients (32.4%) had no insulin resistance. Although the majority of studied population were insulin resistant, the present study couldn’t demonstrate significant association between hypovitaminosis D and presence of insulin resistance, but we demonstrated a negative correlation between serum 25(OH)D and HOMA-IR (r = -0.048, p value 0.62) that is supported by various studies including NHANES III which disclosed that serum 25(OH)D was inversely associated with measures of insulin resistance including HOMA IR [37]. Chandler et al. [35] reported that vitamin D intake was inversely associated with HOMA-IR and the relationship was independent of age, total body fat, and energy intake. In the Canadian Prospective Metabolism and Islet cell Evaluation (PROMISE) study cohort [38], a significant negative correlation was found between serum 25(OH)D and HOMA-IR (r = -0.29, p < 0.001).

Since insulin secretion and insulin resistance are positively correlated in type 2 diabetes, C-peptide is positively correlated with insulin resistance [39]. One of the valuable finding of
the current study is demonstration of the role of C peptide level as an indicator for insulin resistance that is supported by several findings. All patients with high C peptide had insulin resistance and patients with low C peptide had no Insulin resistance. There is statistically significant difference (P value 0.00) as regards C peptide level among BMI categories, being highest among obese patients. We demonstrated that mean HOMA IR was higher among high CPI category 4.83 ± 4.42 vs. 1.96 ± 1.40. with significant difference (P value 0.00) and significant association between high CPI value and presence of insulin resistance (Odds Ratio for Insulin resistance was 6.27).

**Effect of hypovitaminosis D on glycemic control**

At the current study, we used FBS as an indicator for glycemic control, and based on it, patients were divided into high FBS: FBS 100 mg/dl or more (n=136) and patients with normal FBS: FBS less than 100 mg/dl (n=26) to demonstrate any difference between the 2 groups as regards serum 25(OH)D, insulin status and cardiovascular risk including obesity and hypertension. There was no statistical difference in serum 25(OH)D level among the 2 categories as regards 25(OH)D. Mean serum 25(OH)D level is 8.95± 5.69 in the high FBS category and 7.97± 3.46 in the normal FBS category (P= 0.24).

**Relation between hypovitaminosis D and obesity**

One relevant finding of the present study was a negative correlation between serum 25 (OH)D and BMI (r = -0.059, p 0.457). Several studies have shown that patients with hypovitaminosis D had higher prevalence of overweight or obesity when compared to patients with normal 25(OH)D status [40]. Furthermore, obesity is associated with low serum 25(OH)D levels [41-42]. Raška et al. [27] found significant negative association between 25(OH)D levels and BMI (p=0.01)

We have demonstrated the relation between increased BMI and vitamin D status, insulin resistance, glycemic control and blood pressure for diabetic elderly women.

Concerning serum 25(OH)D level, mean 25(OH)D levels is lowest among obese and overweight women (p value 0.35), that is concordant with most of the published studies which report the inverse relation between BMI and vitamin D. Several clinical and epidemiological studies reported that obese subjects have lower serum concentrations of 25(OH)D with a negative correlation of vitamin D concentrations with BMI and waist circumference [43, 44]. There was also an inverse association between 25(OH)D concentration and BMI [45]. A study involving 243 adults reported a decrease of 0.74 nmol/l of serum 25(OH)D per 1 kg/m2 increase in BMI [46].

**Relation between hypovitaminosis D and HTN**

The majority of study population (114 patients) had history of hypertension and were on antihypertensive medication. We demonstrated a negative correlation between serum 25(OH)D level and systolic hypertension (r = -0.056, p 0.477). several observational studies [47, 48] have suggested links between low 25(OH)D levels and a subsequent higher risk for hypertension. The current study shows an inverse correlation between 25(OH)D and systolic blood pressure that is consistent with several studies which demonstrated association between arterial hypertension and hypovitaminosis D [49,50]. Previous studies showed negative correlation between serum 25(OH)D level and blood pressure [51,52]. The prevalence of arterial hypertension was also associated with reduced serum 25(OH)D levels in several studies [53, 54].

**Relation between hypovitaminosis D and CVD**

The Third National Health and Nutrition Examination Survey revealed that 25(OH)D
levels are associated with important cardiovascular disease risk factors. The prevalence of diabetes mellitus (odds ratio 1.98), obesity (odds ratio 2.29), and arterial hypertension (odds ratio 1.30) were all significantly greater in the lower quartiles of the 25(OH)D serum levels than in the higher quartiles (< 0.001 for all) [11]. Epidemiologic studies have reported a trend toward higher prevalence of ischemic heart disease and hypertension with increasing distance from the equator, and these higher rates are attributed to the higher rates of vitamin D deficiency in regions with less exposure to sunlight [55, 56]. At the current study, the failure to demonstrate the association between hypovitaminosis D and certain cardiovascular disease could be attributed to the absence of vitamin D sufficiency group to compare with hypovitaminosis D groups.

REFERENCES
1. Botros RM, Sabry IM, Abdelbaky RS, et al. (2015): Vitamin D deficiency among healthy Egyptian females. Endocrinol Nutr., 62(7):314-21.
2. Nordin BEC, Peacock M and Aaron J, et al. (1980): Osteoporosis and osteomalacia. Clin Endocrinol Metab., 9:177.
3. MacLaughlin J and Holick MF (1985): Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest., 76(4):1536-1538.
4. Bikle DD (2014): Vitamin D Metabolism, Mechanism of Action, and Clinical Applications. Chemistry and Biology 21: March 20, 319-329.
5. Bashir F, Khan ZU, Qureshi S, et al. (2016): Prevalence of Hypovitaminosis D in Type 2 Diabetes Mellitus and its Relationship with Glycemic Control. J Liaquat Uni Med Health Sci.,15(02):83-9.
6. Takishi T, Gysemas C, Bouillon R, et al. (2010): Vitamin D and diabetes. Endocrinology and Metabolism Clinics of North America, 39:419-446.
7. Sung CC, Liao MT, Lu KC and Wu CC (2012): Role of vitamin D in Insulin Resistance. Journal of Biomedicine and Biotechnology Volume 2012, Article ID 634195
8. Seshadri KG, Tamilselvan B and Rajendran A (2011): Role of Vitamin D in Diabetes. J Endocrinol Metab, 1(2):47-56.
9. Chiu KC, Chu A, Go VL and Saad MF (2004): Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am. J. Clin. Nutr., 79(5):820–825.
10. Das B, Mishra TK, Routray SN, et al. (2013): Vitamin D deficiency: A new risk factor for cardiovascular disease, JIACM, 14(3-4): 247-52.
11. Martins D, Wolf M, Pan D, et al. (2007): Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med.,167(11):1159-65.
12. Grundy SM (2007): Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metabol., 92:399–404.
13. Li YC, Kong J, Wei M, et al. (2002): 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest., 110:229–38.
14. Singh B and Saxena A (2010): Surrogate markers of insulin resistance: A review. World J Diabetes,1(2):36-47.
15. Wallace TM, Levy JC and Matthews DR (2004): Use and abuse of HOMA modeling. Diabetes Care, 27:1487–1495.
16. Prando R, Odetti P, Melga P, Giusti R, Ciuchi E, Cheli V. (1996): Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Postprandial plasma C-peptide level is an indication of insulin dependency. Diabetes Metab, 22:185–191.
17. Haupt E, Haupt A, Herrmann R, Benecke-Timp A, Vogel H, Walter C. (1999): The KID study V: the natural history of type 2 diabetes in younger patients still practising a profession. Heterogeneity of basal and reactive C-peptide levels in relation to BMI, duration of disease, age and HbA1. Exp Clin Endocrinol Diabetes, 107:236–243.
18. Albareda M, Rigla M, Rodriguez-Espinosa J, et al. (2005): Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes. Diabetes Res Clin Pract, 68: 202–206.
19. Mancia G, Fagard R, Narkiewicz K et al. (2013): ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal,34:2159–2219. DOI: http://dx.doi.org/10.1093/eurheartj/eht151
20. Dawson-Hughes B, Mithal A, Bonjour JP, et al. (2010): IOF position statement: vitamin D recommendations for older adults. Osteoporos Int., 21:1151-4. [PMID: 20422154]

21. Hedblad B, Nilsson P, Janzon L and Berglund G (2000): Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabet Med., 17: 299-307.

22. Gayoso-Díz P, Otero-González A, Rodríguez-Alvarez MX, et al. (2013): Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocrine Disorders, 13:47, 26.

23. Iwata M, Maeda S, Kamura Y, et al. (2012): Genetic risk score constructed using 14 susceptibility alleles for type 2 diabetes is associated with the early onset of diabetes and may predict the future requirement of insulin injections among Japanese individuals. Diabetes Care, 35:1763–1770.

24. Ohkura T, Shiochi H, Fujikura Y, et al. (2013). 20/(fasting C-peptide × fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol, 12:21.

25. Funakoshi, S., Fujimoto, S., Hamasaki, A. et al. (2011a): Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation, 2(4):297-303, (J Diabetes Invest, doi:10.1111/j.2040-1124.2010.00096.x, 2011).

26. Isaa G, Giorgino R and Adami S (2001): High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care,24(8):1496.

27. Raška I Jr, Rašková M, Zikán V and Škrha J (2016): High Prevalence of Hypovitaminosis D in Postmenopausal Women with Type 2 Diabetes Mellitus. Prague Medical Report,117(1):5–17.

28. Muscogiuri G, Nuzzo V, Gatti A, et al (2016): Hypovitaminosis D: a novel risk factor for coronary heart disease in type 2 diabetes? Endocrine., 51(2):268-73. doi: 10.1007/s12020-015-0609-7. Epub 2015 May 1.

29. Deepika G, Veeraiah N, Govardhan B and Reddy DN (2015): Role of vitamin d status in diabetes mellitus patients; variation with age, sex, season and ethnicity in indian population. Journal of Science, 5(9): 807-813.

30. Deleskog A, Hilding A, Brismar K, et al. (2012): Low serum 25-hydroxyvitamin D level predicts progression to type 2 diabetes in individuals with prediabetes but not with normal glucose tolerance. Diabetologia, 55(6):1668–1678.

31. Boucher BJ, Mannan N, Noonan K, et al. (1995): Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in East London Asians. Diabetologia, 38(10):1239–1245.

32. Özkan B and Döneray H (2011): The nonskeletal effects of vitamin D. Çocuk Sağl?m? ve Hastal?klar? Dergisi,54:99-119.

33. Taverna MJ, Pacher N, Bruzzo F, et al. (2001): Beta-cell function evaluated by HOMA as a predictor of secondary sulphonylurea failure in Type 2 diabetes. Diabetic medicine: a journal of the British Diabetic Association, 18(7):584 8. PMID: 11553190.

34. Shim WS, Kim SK, Kim HJ, et al. (2006): Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes. European journal of endocrinology / European Federation of Endocrine Societies.155(4):615–22. doi: 10.1530/eje.1.02249 P

35. Chandler PD, Giovannucci EL, Scott JB, et al. (2015): Effects of Vitamin D Supplementation on C-peptide and 25 hydroxyvitamin D Concentrations at 3 and 6 Months. Sci. Rep., 5:10411; doi: 10.1038/srep10411.

36. Harinarayan CV, Arvind S, Joshi S, et al. (2014): Improvement in Pancreatic beta Cell Function with Vitamin D and Calcium Supplementation in Vitamin D Deficient Non-Diabetic Subjects. Endocr Pract., 20(2):129-38.

37. Scragg R, Sowers M and Bell C (2004): Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care, 27(12):2813–2818.

38. Kayaniyl S, Vieth R, Retnakaran R, et al. (2010): Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care, 33(6):1379-81.

39. Iwao T, Sakai K and Sata M (2013): Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes. Journal
of diabetes and its complications, 27:87–91, doi: 10.1016/j.jdiacomp.2012.07.001.

40. Miñambres I, Sánchez-Quesada JL, Vinagre I, et al. (2014): Hypovitaminosis D in type 2 diabetes: relation with features of the metabolic syndrome and glycemic control. Endocr. Res., 40(3):160–165.

41. González-Molero I, Rojo-Martínez G, Morcillo S, et al. (2013): Hypovitaminosis D and incidence of obesity: a prospective study. Eur. J. Clin. Nutr., 67(6):680–682.

42. Vimaleswaran KS, Berry DJ, Lu C, et al. (2013): Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PloS Medicine, 10(2): Article ID e1001383.

43. Taheri E, Saedisomeolia A, Djalali M, et al. (2012): The relationship between serum 25-hydroxy vitamin D concentration and obesity in type 2 diabetic patients and healthy subjects. J Diabetes Metab Disord., 11:16. doi:10.1186/2251-6581-11-16.

44. De Pergola G, Nitti A, Bartolomeo N, et al. (2013): Possible role of hyperinsulinemia and insulin resistance in lower vitamin D levels in overweight and obese patients. Biomed Res Int, 2013:921348. doi:10.1155/2013/921348

45. Parikh SJ, Edelman M, Uwaifo GI, et al. (2004): The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab, 89:1196-9.

46. Mcgill AT, Stewart JM, Lithander FE, et al. (2008): Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr J., 7:1-5

47. Forman JP, Giovannucci E, Holmes MD, et al. (2007): Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension., 49:1063-9. [PMID: 17372031].

48. Burgaz A, Byberg L, Rautiainen S, et al. (2011): Confirmed hypertension and plasma 25(OH)D concentrations amongst elderly men. J Intern Med., 269:211-218.

49. Chandana SR, Kocharla LP, Harris SS and Kakarala RR (2009): Association of Vitamin D Deficiency with Hypertension in Uninsured Women. Journal of Health Disparities Research and Practice, 3(1): 43–52.

50. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. (1998): Hypovitaminosis D in medical inpatients. N Engl J Med., 338(12):777-783.

51. Landin-Wilhelmsen K, Wilhelmsen L, Wilske J, et al. (1995): Sunlight increases serum 25(OH) vitamin D concentration whereas 1,25(OH)2D3 is unaffected. Results from a general population study in Göteborg, Sweden (The WHO MONICA Project). Eur J Clin Nutr., 49(6):400-407.

52. Muray S, Parisi E, Cardus A, et al. (2003): Influence of vitamin D receptor gene polymorphisms and 25-hydroxyvitamin D on blood pressure in apparently healthy subjects. J. Hypertens., 21:2069-2075.

53. Garnage-Yared MH, Chedid R, Khalife S, et al. (2009): Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur. J. Endocrinol.,160(6):965-971.

54. Pasco JA, Henry MJ, Nicholson GC, et al. (2009): Behavioural and physical characteristics associated with vitamin D status in women. Bone, 44:1085-1091.

55. Grimes DS, Hindle E and Dyer T (1996): Sunlight, cholesterol and coronary heart disease. QJM., 89:579-89. [PMID: 8935479].

56. Rostand SG (1997): Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension, 30:150-156. [PMID: 9260973]